<\/p>\n
TRex Bio (TRXB US)<\/strong> may have found a place in the IPO market, but investors were not willing to pay a premium on day one. The clinical-stage biotech priced its offering at the low end of the range, opened below issue and spent the session trading in a tight band before closing flat at $14.00. The debut reinforces a developing theme: the biotech IPO window remains open, but meaningful first-day premiums are far from guaranteed.<\/p>\n TRex Bio (TRXB) priced 8.34 million shares at $14.00, the low end of its $14\u2013$16 marketed range, raising approximately $116.8 million in gross proceeds. The stock opened at $13.50, a 3.6% discount to the IPO price, before stabilizing and finishing its first session at $14.00, unchanged from issue.<\/p>\n Trading activity was relatively subdued, with just 1.26 million shares changing hands during the opening session, equivalent to approximately 15% of the shares offered.<\/p>\n The book finished multiple times oversubscribed, supported by stable conversions among healthcare-dedicated investors. However, the allocation was highly concentrated, with the top 10 accounts receiving approximately 80% of the offering.<\/p>\n Retension Pharmaceuticals (RTSN)<\/strong> delivered a disappointing first day on the public markets, with the micro-cap biotech opening sharply below its IPO price before staging a modest recovery. The company priced 3.75 million shares, upsized from the initially marketed 3.3 million, at $12.00 per share, the midpoint of its offering range.<\/p>\n The stock opened at $10.00, a 16.7% discount to the IPO price, before sliding to an intraday low of $9.66. Shares recovered during the session to close at $10.53, still down 12.3% from issue. Trading volume remained below 800,000 shares, reflecting limited aftermarket activity and little fanfare surrounding the debut.<\/p>\n The upsizing suggested sufficient demand to expand the offering, but the weak opening and inability to approach the $12.00 issue price highlighted the challenges facing smaller, early-stage biotechnology companies in the current IPO environment.<\/p>\n The biotech IPO calendar remains active, with Iambic Therapeutics (IAM)<\/strong> scheduled to debut Thursday, October 15, followed by City Therapeutics (CTY)<\/strong> on Friday, October 16. Iambic is developing AI-designed small-molecule medicines for cancer and other serious diseases, while City Therapeutics is advancing RNA interference (RNAi)-based therapies designed to selectively silence disease-causing genes. Both offerings will provide another read on investor appetite for emerging biotech companies and whether the sector can sustain IPO momentum amid a more selective issuance environment.<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[1536],"tags":[],"class_list":["post-33339","post","type-post","status-publish","format-standard","hentry","category-subscriber-content"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/33339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=33339"}],"version-history":[{"count":1,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/33339\/revisions"}],"predecessor-version":[{"id":33340,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/33339\/revisions\/33340"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=33339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=33339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=33339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Retension Pharmaceuticals (RTSN): Micro-Cap Biotech Debut Falls Flat<\/h2>\n
\n